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Abstract 
 
Purpose: To evaluate the extent to which intensity modulated arc therapy (IMAT) for 
high-grade gliomas is comparable to 3-dimensional conformal radiotherapy (3DCRT) in 
relation to the dose delivered to normal brain tissue, PTV conformity and the dose 
delivered to brainstem and optic chiasma. 
 
Method: Sixteen randomly selected 3DCRT treatment plans of grade 3 gliomas were 
re-planned using an IMAT planning technique and dose-volume histograms were 
compared. Primary outcomes were maximum, mean, 1/3 and 2/3 doses to normal brain 
tissue (NBT) outside the PTV. Also the maximum, mean, D50 and D20 doses to PTV.  
Secondary outcomes were maximum and mean doses to the brainstem and optic chiasm. 
Wilcoxon signed rank test was used to compare data.  
 
Results: IMAT led to a statistically significant increase in mean dose to NBT (34.4 v 
33.3 Gy, (p = 0.047) but a statistically significant reduction in maximum dose to NBT 
(62.7 v 63.8 Gy, p = 0.004) compared to 3DCRT.  IMAT led to statistically significant 
reductions in maximum, D50 and D20 doses to the PTV (63.3 v 64.7 Gy, p = 0.001; 
60.0 v 60.7 Gy, p = 0.001 and 60.5 v 61.8 Gy, p = 0.002 respectively). No statistically 
significant differences were seen in doses to brainstem and optic chiasm. 
 
Conclusion: IMAT is at least comparable to 3DCRT in relation to minimising dose to 
normal brain tissue and ensuring good PTV conformity. Doses delivered to OARs using 
IMAT were also comparable to 3DCRT. This study supports the continued use of 
IMAT for the treatment of high-grade gliomas. 
 
Keywords: Intensity modulated arc therapy; High-grade glioma; 3D conformal 
radiotherapy; Radiotherapy planning; Dose volume histograms. 
 
 
 
 
Introduction  
Gliomas are the most common primary tumours of the central nervous system and their 
management has historically been one of the most challenging fields in medicine.1  
Malignant gliomas are widely infiltrative in their extension with indistinct tumour 
margins that are difficult to accurately define2, 3 and delivering radiotherapy is complex 
due to the proximity between tumour and organs at risk (OAR).  
Cognitive symptoms for patients with high-grade gliomas (HGG) can vary from acute 
to chronic memory loss, personality change, confusion, speech problems and severe 
headaches.3 Other common symptoms of HGG include muscle weakness, visual 
symptoms, and changes in sensation.4 Alongside the neurocognitive damage caused by 
the tumour, the effect of radiation to normal brain tissue (NBT) also results in cognitive 
impairment5 and can be one of the more troubling side-effects of radiotherapy to the 
brain.6,7  
In practice many departments have progressed to intensity modulated arc therapy 
(IMAT) also referred to as RapidArc and volumetric-modulated arc therapy (VMAT) 
from the manufacturers of Varian and Elekta respectively. VMAT techniques make 
it easier to target brain tumours whilst reducing dose to critical structures nearby3,7. 
Such damage limitation strategies are increasingly important for the long term clinical 
outcome of patients with HGG who are benefiting from combined chemo-radiation 
programmes.8 However, a recent review by Teoh et al.3 has raised concerns regarding 
the progress to IMAT as the optimal method of treatment delivery; specifically with 
regards the dose to NBT from IMAT compared to to 3-dimensional conformal 
radiotherapy (3DCRT).  
 
As survival outcomes improve for patients with HGG3, 8, an increase in number of 
patients suffering from late effects of radiation may also be possibly seen. Hence, 
innovative methods to minimise treatment-related, long-term toxicities are needed to 
further improve outcomes for these patients.9  
 
 
Purpose 
This study was a service evaluation of local department practice which has progressed 
from 3DCRT to IMAT as the standard technique used for treating brain tumours. This 
study set out to compare dose volume histograms (DVH) of previously treated 3DCRT 
plans with corresponding IMAT plans based on the same patient data. The primary 
outcome was the maximum, mean, 1/3 and 2/3 doses to the NBT outside of the planning 
target volume (PTV) see Table 1. The maximum, mean, D50 and D20 doses to the PTV 
were also analysed (Table 2). The D50 was analysed as this is the median dose to the 
PTV. The D20 is where the highest dose is received by 20% of the PTV. D20 was 
evaluated as a measure of the homogeneity of the dose within the PTV, according to 
department protocol; the maximum dose, Dmax, was used rather than D98 as this metric 
is used in the department protocol. Secondary outcomes were maximum and mean 
doses to the brainstem and optic chiasm (Table 3). 
 
Method 
Sixteen 3DCRT treatment plans of WHO grade 3 gliomas created between 2011 and 
2013 were randomly selected. The sample size is comparable with similar studies.10-13  
The 3DCRT treatment plans were prescribed 60 Gy in 30 fractions, and calculated with 
6MV photons, adhering to department protocols. All patients were immobilised supine 
in a beam direction shell.  
The 3DCRT treatment plans contours were based on ICRU report 50 & 62.14, 15 Gross 
tumour volume (GTV) was defined as the contrast-enhancing tumour on a T1-weighted 
magnetic resonance image fused with a computed tomography (CT) scan, both 2.5mm 
slice thickness. The GTV and the post-operative tumour bed were expanded by 2.5cm 
(in three dimensions) within anatomic routes of spread to create the clinical target 
volume (CTV). Any oedema noted on the scans was also included in the CTV. The 
CTV was then expanded isotropically by 0.5cm to create the PTV. Contoured OARs 
were the brainstem, optic chiasm, right and left optic nerves, retinas, lenses, lacrimals 
and the normal brain. Treatment plan 2, did not have the optic chiasm contoured owing 
to increased distance between the tumour and the optic chiasm.  
IMAT Planning 
The 3DCRT treatment plans were re-planned with the IMAT technique using the 
Eclipse Varian Medical Planning System version 13.6 (Varian Medical Systems, Palo 
Alto, CA). The addition of ICRU report 8316 was used for creating the IMAT treatment 
plans. For the purpose of this study it was decided to use ‘like for like’ with the 
prescription of 60 Gy in 30 fractions.  
 
The OARs were at least two slices thick, so that meaningful DVH could be calculated. 
A margin of 3mm planning risk volume (PRV) was added to the OARs. Where the PTV 
overlapped an OAR, the overlap region was designated only as OAR rather than PTV, 
using the ‘Boolean’ technique and creating an additional PTV. Therefore the original 
PTV was modified to exclude the OAR, as illustrated by the exclusion of the brainstem 
from the PTV in Figure 1. None of the CTVs overlapped with OARs. 
 
The IMAT plans were created with two goals in mind: firstly to achieve PTV coverage 
without violating PTV conformity, OAR doses and avoid hotspots. Secondly to reduce 
OAR doses as much as possible without compromising the PTV coverage and 
conformity. Following department protocol the maximum dose within the PTV was 
105% and the minimum dose within the PTV was 95%. 
 
IMAT plans were created using two full gantry rotation arcs. Several studies have 
found that the use of two arcs result in better plan quality as using a single arc is 
insufficient to achieve dose constraints.3, 10, 11  
Analysis 
A comparative visual dosimetric analysis was performed on the thirty-two CTs and the 
DVHs of each treatment plan were statistically compared. The statistical analysis of 
tolerance doses for the NBT, brainstem and optic chiasm were made using the 
QUANTEC dose tolerance data by Marks et al.17 and the department protocol as 
surrogate (Table 4). 
 
Mean doses were not considered clinically relevant for the serial OARs: optic chiasm, 
and brainstem, but was relevant for the parallel OARs: retina and lens17-19, so it was 
ensured that ipsi-lateral (if possible) and contra-lateral doses to OAR were within their 
tolerance.  
 
The Wilcoxon matched-pair signed-rank test for non- parametrically distributed data 
was used to compare the means between 3DCRT and IMAT treatment plans. All 
statistical tests were two-tailed. SPSS software version 24 was used for statistical 
analysis.  
 
Results 
Tables 1, 2 and 3 illustrate the results for NBT, PTV and OAR data respectively. 
 
Figures 2, 3 and 4 illustrate the data in boxplot form. Extreme outliers are marked with 
an asterisk (*) on the boxplot and mild outliers are marked with a circle (O) on the 
boxplot.20  
 
Discussion 
Study findings 
 
3DCRT and IMAT technique treatment plans for patients with HGGs (grade 3) were 
analysed. The first question addressed was; which is the better technique in regards to 
delivering a lower integral dose to the NBT outside of the PTV? The second question 
addressed was; which technique was better in regards to optic chiasm and brainstem 
(OAR) sparing. The PTV coverage was also assessed to determine if low dose to the 
NBT and OAR sparing was achieved at the cost of PTV coverage.  
 
Through IMAT, a larger volume of NBT was typically irradiated with a small dose 
resulting in an overall higher dose; this is illustrated in Figure 5.  
 
This study found that the PTV coverage using 3DCRT decreased significantly if located 
nearby the brainstem Figure 1 and optic chiasm Figure 7. This was because the dose 
limits were lower to the OAR (Table 4), in comparison to the prescribed dose aimed at 
the tumour (60 Gy). Wagner et al.11 noted that the PTV coverage decreased to 68.2% of 
the volume covered by the prescribed dose using 3DCRT. This is because the single 
fraction to OAR had to be reduced to 1.8 Gy; reducing the dose to the tumour 
concurrently. This implicates the lower biological dose delivered to the tumour. Wagner 
et al.11 concluded that these patients should therefore not be treated with 3DCRT 
technique due to the close proximity of PTV and OAR.  
 
A significant difference was shown (Table 1 and Figure 2) between the two techniques 
for NBT mean (p=0.047) and NBT max (p=0.004). However it is important to consider 
that the Wilcoxon signed rank test illustrates p-value based on the range difference. The 
NBT is not defined as an OAR because planners experience with Eclipse has shown for 
HGG that the brain dose is not reduced with the use of normal brain planning goals. The 
volume of PTV affects the dose the NBT receives, for example if the PTV is covering 
1/3 of the NBT then it is difficult for the dose to be within tolerance. Thus, the 
likelihood of a small difference in increase or reduced dose to the NBT being clinically 
significant is modest when treating a high volume of the brain to a high total dose. 
Hence, it is important to not use the statistical values alone in order to reach a 
conclusion.  
 
A reduction of NBT max with IMAT from 63.76 Gy to 62.73 Gy is unlikely to lead to a 
noticeable reduction in symptomatic necrosis based on the Quantec data17. This 
reduction in IMAT dose for NBT max possibly balances the small increase by IMAT 
for NBT mean. The average difference in dose for the NBT 1/3 was +2.3 Gy more 
delivered by IMAT, but no significant difference (p=0.134) was illustrated, whereas this 
difference in actual dose is generous, based on the prescription dose. 
 
Therefore, based on this analysis of a small sample, there is probably no clinically 
important difference for NBT outcomes. 
 
The statistical data for PTV max, mean, D50 and D20 doses was comparable between 
both techniques (Table 2). The IMAT techniques offer good PTV coverage and 
conformity even when the PTV was close to OARs (Figure 1 and 7). Only parts of the 
PTV, overlapping with an OAR, achieved a lower dose of approximately 54 Gy to the 
PTV in PRV created.  
 
Depending on the PTV location, not all OARs can be taken in to the optimisation 
process. This was also evident in the Sharyan et al.10 study, in which the maximum dose 
to the right optic nerve was higher than left optic nerve due to the tumour position being 
on the right. However, in our study the DVH of treatment plan 1 shows higher dose 
delivered with IMAT to the NBT, whereas treatment plan 4 illustrated an overall higher 
dose delivered with 3DCRT (Figure 6). Sharyan et al.10 demonstrated that there 
were no significant differences in the PTV conformity index between the two 
modalities (p=0.462).  
 
Sharyan et al.10 found the brainstem maximum dose was within the tolerance criteria 
<54 Gy for IMAT but exceeded the criteria in 3DCRT at 60.97 Gy. Our study found a 
small but statistically significant difference for the brainstem mean between the two 
techniques (p=0.044), demonstrating an increase in maximum dose +2.39 Gy to the 
brainstem with IMAT (Table 3 and Figure 4). The DVHs of treatment plan 5 
demonstrated equal doses delivered to the brainstem using both techniques. Whereas for 
plan 4 and 11 the IMAT dose had a steeper drop off as desired in radiotherapy 
treatment. The brainstem and optic chiasm are serial organs, so it is vital to maintain 
their dose within tolerance17.  
 
The optic chiasm max and mean doses were comparable with both modalities. Similar 
to Sharyan et al.10 study in which the optic chiasms were within tolerance levels for both 
techniques. In our study IMAT was able to spare the brainstem and optic chiasm for 
more treatments plans. Thus patients with a tumour nearby optic chiasm and brainstem 
may benefit treatment with IMAT. Figure 7 illustrates the difference in dose delivered 
by both techniques to the optic chiasm in DVHs. 
 
Our study and evidence from previous studies11-13, 21 demonstrated that IMAT can lead 
to reductions in maximum doses delivered to critical structures but at the expense of 
increased mean dose to the NBT. There is currently insufficient evidence to demonstrate 
if the increase in dose to NBT compared to the reduced dose to OARs is statistically or 
clinically significant. It is important to acknowledge that the Quantec data by Marks et 
al.17 was produced based on data using 3DCRT techniques, so can not be equally 
applicable to the relatively new IMAT techniques. Nevertheless, it is evident that IMAT 
does lead to better PTV coverage. 
 
 
Limitations 
It is important to consider that the 3DCRT treatment plans used in this study were 
phased treatments. The 1st phase delivered 2 Gy per fraction to the PTV even if there 
was OARs involved, and the 2nd phase of the treatment resulted in large uncovered areas 
in the PTV affecting the PTV’s overall coverage and conformity. 
 
In this study planning goals for each treatment plan were met so it was deemed 
‘clinically acceptable’. The planner in this study did not continue optimising to achieve 
the best plan possible due to time constraints. Further optimisation may have led to 
larger differences than those seen in tables 1-3.  
 
This study did not set out to evaluate time differences but, as identified by Sharyan et 
al.10, it was noted that IMAT techniques required longer to plan. However, advantages 
of IMAT (relating to PTV coverage and OAR sparing) may outweigh the limitations 
associated with additional planning time. 
 
Furthermore lower number of monitor units with IMAT, implies less scattered 
radiation12 and significant reduction of delivery time demonstrated in many studies.10-13 
Consequently, organ motion during treatment delivery is less problematic and patient 
comfort is enhanced through as time spent immobilised in a beam direction shell is 
reduced. Patient throughput may also be increased as a result of reduced treatment 
times.  
 
HGG are classified as grade 3 and 4. Our study included only grade 3 whereas other 
studies included patients with both grade and so definitive comparisons are not possible.  
Conclusion 
Our evaluation found that IMAT was at least comparable to 3DCRT in relation to 
minimising dose to normal brain tissue and ensuring good PTV conformity. Improved 
PTV conformity with IMAT was particularly noted in cases where the PTV was in close 
proximity to OARs.  Similarly doses delivered to OARs using IMAT were also 
comparable to 3DCRT.  
 
This study supports the continued use of IMAT for the treatment of high-grade gliomas.  
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Illustrations 
Table 1. Statistics for NBT data (Gy) 
 NBT Mean NBT Max NBT 1/3 NBT 2/3 
IMAT 3DCRT IMAT 3DCRT IMAT 3DCRT IMAT 3DCRT 
No. of Plans 
 
Mean ± 1SD 
16 
 
34.44 ± 
8.47 
 
 
33.30 ± 
8.65 
16 
 
62.73 ± 
0.66 
 
 
63.76 ± 
1.18 
16 
 
44.27 ± 
12.34 
 
 
45.47 ± 
13.16 
16 
 
23.02 ± 
11.29 
 
 
20.72 ± 
13.36 
Range 2348 2149 6264 6267 2760 2260 542 245 
Difference/ 
(SS) 
+1.14 (p= 0.047) -1.03 (p= 0.004) -1.2 (p= 0.054) +2.3 (p= 0.134) 
Abbreviations: SD = Standard Deviation, SS = Statistical Significance 
**Values are expressed as p-value (p=), mean ± 1 standard deviation or as mean value 
according to data distribution shown in Table 1 
Illustrations 
Table 2. Statistics for PTV data (Gy) 
 PTV Mean PTV Max PTV D50 PTV D20 
IMAT 3DCRT IMAT 3DCRT IMAT 3DCRT IMAT 3DCRT 
No. of Plans 
 
Mean ±        
1SD 
16 
 
59.91 ± 
0.06 
 
 
59.98 ± 
0.98 
16 
 
63.30 ± 
0.58 
 
 
64.69 ± 
1.23 
16 
 
59.98 ± 
0.08 
 
 
60.68 ± 
0.53 
16 
 
60.48 ± 
0.33 
 
 
61.84 ± 
0.76 
Range 59.860 57.161.2 62.464.2 62.567.8 59.860.1 59.961.8 60.161.5 60.363.2 
Difference/ 
(SS) 
-0.07 (p= 0.328)  -1.39 (p=0.001)  -0.7 (p=0.001)  -1.36 (p=0.002)  
Abbreviations: SD = Standard Deviation, SS = Statistical Significance 
**Values are expressed as p-value (p=), mean ± 1 standard deviation or as mean value 
according to data distribution shown in Table 2 
Illustrations 
Table 3. Statistics for OAR data (Gy) 
 Brainstem Mean Brainstem Max Optic Chiasm Mean Optic Chiasm Max 
IMAT 3DCRT IMAT 3DCRT IMAT 3DCRT IMAT 3DCRT 
No. of Plans 
 
Mean ±        
1SD 
16 
 
29.52 ± 
17.20 
 
 
27.13 ± 
17.50 
16 
 
42.62 ± 
18.38 
 
 
42.64 ± 
18.12 
15 
 
36.91 ± 
19.78 
 
 
35.23 ± 
20.77 
15 
 
39.50 ± 
20.23 
 
 
38.73 ± 
21.90 
Range 2.250 1.249.7 5.853.9 4.055.5 4.252.8 1.853.9 5.056.7 2.254.4 
Difference/ 
(SS) 
+2.39 (p= 0.044)  -0.02 (p=0.691)  +1.68 (p=0.191)  +0.77 (p=0.691)  
Abbreviations: SD = Standard Deviation, SS = Statistical Significance 
**Values are expressed as p-value (p=), mean ± 1 standard deviation or as 
mean value according to data distribution shown in Table 3.  
 
Illustrations 
Table 4. Tolerance doses used for creating treatment plans 
Organ At Risk Tolerance Dose Endpoint 
 
Brainstem Max <54Gy Severe  
neurological effects 
Optic Chiasm Max <55Gy Optic neuropathy/ 
Blindness 
NBT (1/3) Max <60Gy Symptomatic  
necrosis 
NBT (2/3) Max <50Gy Symptomatic 
 necrosis 
NBT (3/3) Max <45Gy Symptomatic  
necrosis 
Adapted from department protocols and Marks et al.17 
 
Table
Illustrations 
(a)                                                                                   (b)       
Figure 1.  Illustrates the dose distribution with the exclusion of brainstem from PTV for (a) 
3DCRT and (b) IMAT for the same patients plan at the same CT slice. Blue line = PTV, Pink 
line = Brainstem. 
 
Illustrations 
Dose delivered to Normal Brain Tissue (NBT) 3DCRT vs IMAT 
 
Figure 2. Boxplot illustrating statistics for NBT data 
 
Illustrations 
Dose delivered to Planning Target Volume (PTV) 3DCRT vs IMAT 
 
Figure 3. Boxplot illustrating statistics for PTV data 
 
Illustrations 
Dose delivered to Organs at Risk (OAR) 3DCRT vs IMAT 
 
Figure 4. Boxplot illustrating statistics for OAR data 
 
Difference in dose delivered to the mean and maximum of the OAR between both techniques.   
Illustrations 
(a)                                                                                   (b)       
 
Figure 5. Illustrates the same axial slice of treatment plan 3 for both techniques, (a) 3DCRT 
and (b) IMAT. A larger volume of the NBT is receiving dose, using IMAT. 
 
Illustrations 
Treatment plan 1, illustrating more dose delivered with IMAT to the NBT. 
 
Treatment plan 4, illustrating more dose delivered with 3DCRT to the NBT 
 
Figure 6. Illustrates the DVHs of the NBT for two different treatment plans. 
Treatment plan 1; ☐=IMAT, Δ=3DCRT.  Treatment plan 4; ☐=3DCRT, Δ=IMAT
 
Illustrations 
a)                                                                                   (b)       
 
Figure 7. Illustrates the poor PTV coverage and conformity of the PTV using the 3DCRT 
technique, compared to the IMAT technique, due to the presence of the optic chiasm.  
(a)= 3DCRT, Green line = Optic chiasm, Orange line = Brainstem. 
(b)= IMAT, Purple line = Optic chiasm, Pink line = Brainstem. 
Blue line= PTV in both treatment plans. 
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for the first and second author however 
SHU is given the designation of 2 
 
Amended as requested 
The word image is used in the title, 
abstract, and body of the report however 
there is no imaging analysis or 
modulation in the report.  Consider 
changing this to intensity or volumetric 
(VMAT).  
 
Changed to VMAT as suggested. 
There are typographical errors in the 
results section of the abstract where 
(p=0,004 & p=0,0001) the commas 
should be a periods (. not ,) 
 
Corrected 
The reference (2) by Gould is an online 
review of the Shaffer (13) article and 
mentions VMAT not image modulated arc 
therapy.  This is also not a peer reviewed 
article. 
 
Have changed as it not accessible. 
References (2, 4, 14, 15, 21) are not 
considered to be suitable as they are not 
peer reviewed or accessible by the 
reader.  Reference 21 is repeated 
 
Amended, 14 and 15 were department 
protocols hence not externally 
accessible. These have been removed 
from the reference list and in text 
citations.  
Reference 20 is quite dated (24 years 
old) there are more recent applicable 
references to cite. 
 
Changed to a recent one. 
Indicate why you have chosen D50 and 
D20 as values to compare for your 
article.  Most literature compare D98, 
D50 and D2 values. 
 
D50= Median dose to PTV, ICRU 83  
 
D20= Highest dose received by 20% of 
the PTV. D20 was evaluated as a 
measure of the homogeneity of the 
dose within the PTV, according to 
department protocol; the maximum 
dose, Dmax, was used rather than D98 
as this metric is used in the 
department protocol. 
Spelling of optimization in the limitations 
sections should be changed to 
optimisation 
 
Corrected 
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Comments 
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Please select only 5 key words to comply 
with house style 
 
Selected only 5 
Please check affiliation of second author 
and add an address for corresponding 
author, landline and email address here. 
 
Added 
Please reconsider some of your 
references as some of them are old and 
there have been some more recent 
papers supporting your points that you 
can also cite-the references need to be 
checked as one is repeated. 
 
Checked references, repeat had been 
removed and more recent ones have 
been included removing the old ones. 
For all references please check-ref 1 add 
city and country of publication , ref 2 and 
all online refe add last date accessed. 
 
Amended by adding last accessed date 
on online references and adding the 
publication details etc on reference 1. 
For all refs with 3 names and then et al, 
the Journals style is to name all the first 
6 authors and if there are more then use 
et al. 
 
Corrected as requested. 
Please check your figures and tables-is 
table 4 referred to in the text anywhere? 
 
Checked and revised, table 4 has been 
removed. 
In the methods section you say 'All 
patients immobilised supine -can you add 
a sentence to say how? 
 
Added more detail. 
Please clarify why you have chose D50 
etc. 
 
D50= Median dose to PTV, ICRU 83  
 
D20= Highest dose received by 20% of 
the PTV. D20 was evaluated as a 
measure of the homogeneity of the 
dose within the PTV, according to 
department protocol; the maximum 
dose, Dmax, was used rather than D98 
as this metric is used in the 
department protocol. 
In the IMAT planning section please add 
the name, city and country of 
manufacturer after the treatment 
planning system (again this is 
convention) 
 
Added the requested information. 
 
